Poly-arginine-18 (R18) Confers Neuroprotection through Glutamate Receptor Modulation, Intracellular Calcium Reduction, and Preservation of Mitochondrial Function.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
29 Jun 2020
Historique:
received: 22 05 2020
revised: 23 06 2020
accepted: 26 06 2020
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 20 2 2021
Statut: epublish

Résumé

Recent studies have highlighted that a novel class of neuroprotective peptide, known as cationic arginine-rich peptides (CARPs), have intrinsic neuroprotective properties and are particularly effective anti-excitotoxic agents. As such, the present study investigated the mechanisms underlying the anti-excitotoxic properties of CARPs, using poly-arginine-18 (R18; 18-mer of arginine) as a representative peptide. Cortical neuronal cultures subjected to glutamic acid excitotoxicity were used to assess the effects of R18 on ionotropic glutamate receptor (iGluR)-mediated intracellular calcium influx, and its ability to reduce neuronal injury from raised intracellular calcium levels after inhibition of endoplasmic reticulum calcium uptake by thapsigargin. The results indicate that R18 significantly reduces calcium influx by suppressing iGluR overactivation, and results in preservation of mitochondrial membrane potential (ΔΨm) and ATP production, and reduced ROS generation. R18 also protected cortical neurons against thapsigargin-induced neurotoxicity, which indicates that the peptide helps maintain neuronal survival when intracellular calcium levels are elevated. Taken together, these findings provide important insight into the mechanisms of action of R18, supporting its potential application as a neuroprotective therapeutic for acute and chronic neurological disorders.

Identifiants

pubmed: 32610439
pii: molecules25132977
doi: 10.3390/molecules25132977
pmc: PMC7412265
pii:
doi:

Substances chimiques

Neuroprotective Agents 0
Peptides 0
Receptors, Glutamate 0
polyarginine 25212-18-4
Glutamic Acid 3KX376GY7L
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : University Postgraduate Award (UPA) from the University of Notre Dame, Australia.
ID : N/A

Références

Molecules. 2010 Mar 03;15(3):1168-95
pubmed: 20335972
PLoS One. 2018 Mar 7;13(3):e0193884
pubmed: 29513757
FEBS Lett. 2000 Sep 15;481(2):131-6
pubmed: 10996311
Curr Mol Med. 2004 Mar;4(2):149-77
pubmed: 15032711
Pflugers Arch. 2010 Jul;460(2):525-42
pubmed: 20229265
Cell Calcium. 2004 Sep-Oct;36(3-4):257-64
pubmed: 15261481
Front Neurosci. 2015 Dec 16;9:469
pubmed: 26733784
J Am Soc Nephrol. 2011 Jun;22(6):1041-52
pubmed: 21546574
Neuromolecular Med. 2017 Sep;19(2-3):271-285
pubmed: 28523591
Biochem Biophys Res Commun. 1995 Dec 5;217(1):144-9
pubmed: 8526902
Mol Pharmacol. 2002 May;61(5):1081-8
pubmed: 11961125
Pain. 2015 Jul;156(7):1247-1264
pubmed: 25782368
J Biol Chem. 1991 Sep 15;266(26):17067-71
pubmed: 1832668
Antioxid Redox Signal. 2008 Mar;10(3):601-19
pubmed: 17999629
J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004
pubmed: 25669902
Diabetes. 1998 Jul;47(7):1114-20
pubmed: 9648836
Acta Pharmacol Sin. 2003 Aug;24(8):746-50
pubmed: 12904272
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2518-27
pubmed: 23776240
J Cell Sci. 2005 Aug 1;118(Pt 15):3339-51
pubmed: 16079278
FASEB J. 2015 Nov;29(11):4589-99
pubmed: 26195590
Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1057-83
pubmed: 16710759
J Biol Chem. 2011 Oct 28;286(43):37778-92
pubmed: 21832084
Stroke. 2007 Feb;38(2 Suppl):674-6
pubmed: 17261713
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19492-7
pubmed: 19033459
Neurobiol Dis. 2006 Feb;21(2):392-403
pubmed: 16165367
Nat Biotechnol. 1998 Mar;16(3):286-91
pubmed: 9528011
Biochim Biophys Acta. 2009 Nov;1787(11):1374-82
pubmed: 19344663
Biochem Biophys Res Commun. 1997 May 8;234(1):35-8
pubmed: 9168955
Neurobiol Dis. 2019 Jan;121:17-33
pubmed: 30218759
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5631-5
pubmed: 2546162
Biochem Biophys Res Commun. 2002 Jan 11;290(1):47-52
pubmed: 11779131
J Mol Neurosci. 2017 Feb;61(2):235-246
pubmed: 27866326
J Neurochem. 2011 Sep;118(6):1113-23
pubmed: 21749375
Brain Res Bull. 2017 Oct;135:62-68
pubmed: 28964774
J Biol Chem. 2017 Dec 1;292(48):19656-19673
pubmed: 28972171
Front Physiol. 2018 Jul 03;9:806
pubmed: 30018565
Stroke Res Treat. 2016;2016:2372710
pubmed: 27247825
Biochim Biophys Acta. 2015 Oct;1847(10):1075-84
pubmed: 26071084
Neuron. 2002 Mar 14;33(6):849-60
pubmed: 11906693
Br J Pharmacol. 1998 Jul;124(5):905-10
pubmed: 9692775
Nat Rev Mol Cell Biol. 2012 Sep;13(9):566-78
pubmed: 22850819
Fundam Clin Pharmacol. 1999;13(5):535-40
pubmed: 10520725
J Am Soc Nephrol. 2013 Jul;24(8):1250-61
pubmed: 23813215
Neurosci Res. 2017 Jan;114:9-15
pubmed: 27639457
Neurotherapeutics. 2020 Apr;17(2):627-634
pubmed: 31833045
J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):55-61
pubmed: 24814549
J Biol Chem. 2007 Apr 13;282(15):11590-601
pubmed: 17308309
J Neurophysiol. 2002 Sep;88(3):1279-87
pubmed: 12205149
Atherosclerosis. 2014 Sep;236(1):133-41
pubmed: 25036240
Front Neurol. 2020 Feb 25;11:108
pubmed: 32158425
Mol Brain. 2018 Feb 9;11(1):8
pubmed: 29426351
J Am Chem Soc. 2014 Dec 17;136(50):17459-67
pubmed: 25405895
J Cell Mol Med. 2011 Apr;15(4):701-17
pubmed: 21155972
Mol Pharmacol. 2005 Jul;68(1):84-9
pubmed: 15851654
Transl Neurosci. 2017 Nov 15;8:147-157
pubmed: 29177102
Neurosci Lett. 1990 Jul 3;114(2):197-202
pubmed: 1975660
Neuroscience. 2001;108(1):17-26
pubmed: 11738128
ACS Chem Neurosci. 2019 Dec 18;10(12):4800-4809
pubmed: 31710458
J Neurosci. 1996 Jul 1;16(13):4069-79
pubmed: 8753869

Auteurs

Gabriella MacDougall (G)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Institute for Health Research, School of Heath Sciences and Institute for Health Research, The University Notre Dame, Fremantle, WA 6160, Australia.

Ryan S Anderton (RS)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Institute for Health Research, School of Heath Sciences and Institute for Health Research, The University Notre Dame, Fremantle, WA 6160, Australia.
Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, WA 6009, Australia.

Amy Trimble (A)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Institute for Health Research, School of Heath Sciences and Institute for Health Research, The University Notre Dame, Fremantle, WA 6160, Australia.

Frank L Mastaglia (FL)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, WA 6009, Australia.

Neville W Knuckey (NW)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, WA 6009, Australia.
Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, WA 6008, Australia.

Bruno P Meloni (BP)

Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, WA 6009, Australia.
Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, WA 6008, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH